Company intelligence / Profile preview

GemVax & KAEL Co., Ltd.

Daejeon, Daejeon, South Koreagemvax.com ↗

Ownership: Private
Development stage: Phase 2

Overview

GV1001 missed the primary endpoint in a Phase 2a study for Progressive Supranuclear Palsy (PSP) in October 2024, but the company believes the overall data is strong enough to consider advancing to a pivotal trial. The company is also conducting a Phase 2 trial for Alzheimer's disease in the US and Europe. Their pancreatic cancer drug RIAVAX (GV1001) received conditional approval in South Korea in 2014, but this was later revoked in 2020 when the company failed to submit required Phase 3 clinical results.[6][9]

Therapeutic areas: Men's HealthOncologyImmunologyNeurology
Modalities: Synthetic peptidesTherapeutic vaccinesSynthetic peptide vaccines
Industry: Biotech

Drug pipeline

4 assets

tertomotide

3 more assets in the full pipeline.

Partnerships

Samsung Pharm Co., Ltd.

Beyond the preview

Go deeper on GemVax & KAEL Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GemVax & KAEL Co., Ltd..